04 September 2018
A new report by visiongain predicts that the Global Drug Delivery Technologies market will reach $259.1bn in 2020. This forecast and others appear in Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes—published in July 2016. Visiongain is a business information provider based in London, UK.
Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report examines the current and future trends in the growing drug delivery technologies market. As the generic drug industry continues to see rapid growth, big pharma companies will continue to strive for extensions on their product life-cycles. Drug delivery technologies are of high demand not only because of the deep interest shown by pharma companies in recent years but also the dire need to improve patient compliance. Yemi Adebayo, a Pharmaceutical and Medical Devices Analyst at visiongain comments:
“Drug delivery technologies provide ample opportunities for both biopharmaceutical companies that offer services providing new technologies and pharmaceutical companies attempting to extend the product lifecycle of their product. The drug delivery technologies market will see fast growth over the next ten years. The oral drug delivery market remains the most dominant submarket, which is largely due to the convenience of taking drugs orally. However, with increasing numbers of biologic medicines we expect to see the injectable drug delivery tech market grow rapidly over the forecast period. The problem with using the parenteral route for drug delivery is the inconvenience it brings to patients. As such, novel ways of administering biologics will be sought. This, together with the growing burden of an ageing population and rise in chronic diseases in most developed countries will continue to cause demand for new ways of delivering drugs to their intended target.”
In this report, we examine in detail the drug delivery technologies market, and provide analyses and forecasts for regional and national markets. Historical revenues have also been added to strengthen our analysis to demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.
Visiongain’s report provides revenue forecasts to 2026 for the global biologics market, the global vaccines market and the global drug delivery technologies market and the leading regional and national drug delivery technologies markets. The report discusses selected leading companies in the market. These companies include Alkermes, 3M, Skyepharma, Becton Dickinson and Company (BD), Antares Pharma, pSivida, Applied Pharma Research (APR), Ethypharm, Glycologic and NanoPass Technologies
Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 61
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional that needs independent, high quality, original analyses to inform their strategic decisions.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth